An observational study in Urologic Diseases, Male Infertility and Sexual Medicine, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Urologic Diseases with a site in Italy — 4 open to participants now, 7 under way, 3 of them phase 3. Urologic Diseases · Italy.
Among the 22 studies in Urologic Diseases with a site in Italy, this one is one of 3 that started in 2015, is one of 4 observational ones, and was the 20th registered.
221 studies on the registry are indexed under Urologic Diseases; 48 are open to participants now.
Browse Urologic Diseases studies →4 of the 22 studies in Urologic Diseases with a site in Italy are open now. Recruiting first, the newest first:
Istituto Oncologico Veneto IRCCS · Sites in Italy
Ages 18–99
Medtronic · Sites in Italy, United States, Argentina and 38 more countries
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 37 Urologic Diseases studies recruiting now, 24 (65%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 6
First in 2002; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 200 across 49 observational studies indexed under Urologic Diseases.
Median enrollment 102 across the 18 interventional studies, 12,500 across the 4 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 22 have an industry lead sponsor. The 10 most frequent:
IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
IRCCS San Raffaele has 2 studies filed under Urologic Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Urologic Diseases with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT07338292Istituto Oncologico Veneto IRCCSVIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Urologic Diseases with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective observational study on the quality of life of patients attending general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.The data relating to the clinical conditions (disease state, psychological and related to quality of life) of the patients belonging to the above-mentioned clinics will be collected in a specially designed database which will allow us to extract the data in a simple and safe way used for statistical analyses. in clinical research.
The Department of Urology has been engaged for years in the field of medical and surgical research relating to benign and oncological pathologies of the prostate, kidney, excretory tract, testicle, as well as urinary continence and dysfunctions of the sexual and reproductive sphere. The accurate acquisition of clinical and psychometric data before and after any treatment, the follow-up analysis, the attention to the patient's global quality of life (QoL) in relation to the particular organic functions affected by the disease, are at the basis of all the medical advances that can be achieved to guarantee ever better care of the individual's health. In the context of urological clinical practice, outpatient activity plays a fundamental role. This activity, which ranges from general urology to sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology, allows us to come into contact with a large number of patients suffering from the most common uropathologies -andrological .
Numerous studies have demonstrated how the treatment and outpatient management of such patients significantly impacts not only the underlying pathology but also their quality of life.
The outpatient management of the urological patient ranges from the recognition of the basic pathology to the diagnosis through the request for clinical-laboratory-instrumental investigations, to the possible indication for a medical or surgical treatment and to the follow-up of the patient.
The main objectives of this data archive are:
The patient population of interest is characterised by: patients who came for outpatient visits to the general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects belonging to general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.
Other: Observation during time
Evaluation through clinical investigation and questionnaires useful for evaluating the patient's psycho-physical conditions
Sexual function - Erectile Function
Sexual function investigated through: "International Index of Erectile Function" questionnaire IIEF (scoring: 1 - 30 - 6-10: severe; 11-16: Moderate; 17-25: mild; 26-30: absence);
Time frame: Baseline and up to 6 months
Sexual function - premature ejaculation
Premature ejaculation investigated through PEDT questionnaire (; Scoring: 0 - 20. \<=8 absence; 9-10 probable; \>=11 premature ejaculation);
Time frame: Baseline and up to 6 months
Sexual function - male sexual health
Male sexual health investigated through MSHQ questionnaire (25-item, range: 7 - 80, greater score indicating better function and through Androtest (1 - 32; \> 8 = out of the norm);
Time frame: Baseline and up to 6 months
Sexual function - androgen deficiency
Androgen deficiency in elderly males investigated through ADAM questionnaire (range 10 - 50, 10 = absence and 50 = maximal,
Time frame: Baseline and up to 6 months
Sexual function - satisfaction with treatment of erection problems
satisfaction with treatment of erection problems investigated through EDITS questionnaire (range = 0-100; higher scores =more treatment satisfaction),
Time frame: Baseline and up to 6 months
Female sexual function
Female sexual function investigated through "Female Sexual Function Index" questionnaire - FSFI (range 2 - 36, lower scores = worse sexual functioning),;
Time frame: Baseline and up to 6 months
Sexual function - sexual distress
Sexual distress investigated through "Sexual Distress Scale" questionnaire - SDS (range 12- 48, sexual distress = \> 15).
Time frame: Baseline and up to 6 months
Prostate function - Prostatic Symptoms
Prostatic Symptoms investigated through IPSS questionnaire "International Prostatic Symptoms Score": , Scoring 0 -7, 0-7 mild symptoms, 8-19 moderate symptoms, 20-35 severe symptoms
Time frame: Baseline and up to 6 months
Psychological state
Psychological state investigated through Beck Beck Depression Inventory: Range score 1 - 63; 1-10: normal; 11-16: Mild mood disturbance; 17-20: Borderline clinical depression; 21-30: Moderate depression; 31-40: Severe depression; over 40: Extreme depression.
Time frame: Baseline and up to 6 months
Prostate function - Incontinence Questionnaire
Incontinence Questionnaire investigated through ICIQ-SF questionnaire (maximum score of 21; the higher the score, the more severe is the UI, but there is no normal score)
Time frame: Baseline and up to 6 months
Overactive Bladder
Overactive Bladder investigated through OAB-q - Overactive Bladder Questionnaire: the score for each of OAB-q domain are summed and transformed to a score ranging from zero to 100. Higher scores indicate more severe symptoms or better quality of life.
Time frame: Baseline and up to 6 months
Prostate function
Prostate function investigated through National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) questionnaire: total score range from 0 to 43, three subscales addressing pain (score range 0-21), urinary symptoms (score range 0-10), and quality of life (QOL) (score range 0-12)
Time frame: Baseline and up to 6 months
Started Feb 2015 (actual). Primary completion is estimated for Feb 2025, 120 months after the start.
Of 36 observational studies under Urologic Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20. This study's planned 120 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.